BARBARA ANN KARMANOS CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.karmanos.org
Clinical Trials
148
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (138 trials with phase data)• Click on a phase to view related trials
A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions
- Conditions
- HealthyFinancial Toxicity
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT07042191
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
- Conditions
- CancerCancer SurvivorsGastrointestinal CancersNeuroendocrine TumorsMultiple Myeloma, Neoplasms
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 120
- Registration Number
- NCT06908629
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06576115
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT06420167
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Daratumumab/rHuPH20 Co-formulation
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06107738
- Locations
- 🇺🇸
KCI at McLaren Greater Lansing, Lansing, Michigan, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 30
- Next
News
PanTher Therapeutics Initiates Phase 1b Trial of Novel Localized Chemotherapy Film for Pancreatic Cancer
PanTher Therapeutics has dosed the first patient in a Phase 1b clinical trial of PTM-101, an innovative thin film formulation of paclitaxel designed for direct tumor placement in pancreatic ductal adenocarcinoma.
Novel BCMA-Directed CAR T-Cell Therapy Shows Promising Efficacy in Relapsed/Refractory Multiple Myeloma and AL Amyloidosis
A second-generation BCMA-directed CAR T-cell therapy, MDC-CAR-BCMA001, demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma and AL amyloidosis, achieving a 5/6 overall response rate with 4 complete responses.
Karmanos Cancer Institute First to Prescribe FDA-Approved TheraBionic P1 for Advanced Liver Cancer
Karmanos Cancer Institute is the first worldwide to prescribe the TheraBionic P1, an FDA-approved at-home device, for advanced hepatocellular carcinoma.